Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.
Shanghai Fosun Pharmaceutical said a key subsidiary, Fosun Pharma (Xuzhou) Co., Ltd., has obtained approval from China’s National Medical Products Administration to market Venlafaxine Hydrochloride Sustained-release Tablets. The product, a Class 3 chemical drug with a 75mg strength, is indicated for the treatment of depression, including depression with anxiety, and generalized anxiety disorder, broadening the group’s central nervous system portfolio and potentially enhancing its position in the psychotropic medications market.
The approval designates Fosun Pharma (Xuzhou) as both marketing authorization holder and manufacturer, underscoring the subsidiary’s role in the group’s innovative and generic drug pipeline. The move may support Fosun Pharma’s revenue diversification and competitive standing in China’s crowded antidepressant market, as it leverages regulatory clearance to expand access to treatment options for mood and anxiety disorders.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based biopharmaceutical group engaged in the research, development, manufacturing and marketing of chemical and biological drugs, medical devices and healthcare services, with listings in Shanghai and Hong Kong and a focus on both domestic and international pharmaceutical markets.
Average Trading Volume: 2,549,709
Technical Sentiment Signal: Sell
Current Market Cap: HK$70.82B
Learn more about 2196 stock on TipRanks’ Stock Analysis page.